Abdominal obesity-metabolic syndrome quantitative trait locus 2

Summary

Abdominal obesity-metabolic syndrome quantitative trait locus 2 (MONDO:0011566) is a disease. A subtype of abdominal obesity-metabolic syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	abdominal obesity-metabolic syndrome quantitative trait locus 2
Mondo ID	MONDO:0011566
OMIM	605572
UMLS	C1854170
MedGen	344224
GARD	0024808
Is cancer (heuristic)	no

Also known as: abdominal obesity-metabolic syndrome quantitative trait locus 2 · abdominal obesity-metabolic syndrome quantitative trait locus type 2

Disease family

This is a subtype of abdominal obesity-metabolic syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › abdominal obesity-metabolic syndrome › abdominal obesity-metabolic syndrome quantitative trait locus 2

Related subtypes (4): metabolic syndrome X, abdominal obesity-metabolic syndrome 3, LIPE-related familial partial lipodystrophy, abdominal obesity-metabolic syndrome 4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.